arrow
Back
M

Marc Buyse

international drug development institute

101H-index
643Paper Count
4.8WCitation Count
Published Papers 122
Publication Date
Regional variation in clinical-trial risks: a large-scale analysis of 585 clinical trials
err2025-10-01
err0
errOAAI
errDe Viron, Sylviane; Young, Steve; Trotta, Laura; Buyse, Marc
errShare
errSave
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy
err2025-09-01
err0
errOAAI
errSternberg, C. N.; Squifflet, P.; Saad, E. D.; Burdett, S.; Fisher, D.; Kurt, M.; Teitsson, S.; May, J. R.; Patel, M. Y.; Stoeckle, M.; Torti, F.; Cote, R.; Ruggeri, E. M.; Zhegalik, A.; Tierney, J. F.; Collette, L.; Burzykowski, T.; Buyse, M.
errShare
errSave
Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease
err2025-08-29
err0
PREAI
errRod S. Taylor; Hiddo J.L. Heerspink; Marc Buyse; Oriana Ciani; Bruno Detournay; Daniel Gallego; Juan Carlos Julián Mauro; Smeeta Sinha; Marta Trapero-Bertran; Lesley A. Inker
errShare
errSave
Generalized Pairwise Comparisons to Support Shared Decision-Making in the CODA Trial
err2025-03-31
err0
errOAAI
errSalvaggio, Samuel; Monsell, Sarah E.; Heagerty, Patrick J.; De Backer, Mickael; Barre, Emilie; Chiem, Jean-Christophe; Saad, Everardo D.; Buyse, Marc; Flum, David R.
errShare
errSave
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
err2025-03-01
err0
PREAI
errAssaf, Irene; Bregni, Giacomo; Anthoine, Geraldine; Aparicio, Thomas; Artru, Pascal; Ben Abdelghani, Meher; Buyse, Marc; Chibaudel, Benoist; Coart, Elisabeth; Diaz, Marie; Evrard, Camille; Geboes, Karen; Ghiringhelli, Francois; Puleo, Francesco; Raimbourg, Judith; Vandamme, Timon; van den Eynde, Marc; Hendlisz, Alain; Sclafani, Francesco
errShare
errSave
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer
err2024-08-01
err0
PREAI
errBrookman-May, Sabine D.; Buyse, Marc; Freedland, Stephen J.; Miladinovic, Branko; Zhang, Ke; Fendler, Wolfgang P.; Feng, Felix; Sartor, Oliver; Sweeney, Christopher J.
errShare
errSave
Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)
err2024-06-01
err0
PREAI
errSclafani, F.; Bregni, G.; Assaf, I.; Puleo, F.; Vergauwe, P.; Prenen, H.; Diaz, M.; Gokburun, Y.; Sanchez, A. Veron; Anthoine, G.; Moretti, L.; Galdon, M. Gomez; Liberale, G.; Martinive, P.; Geboes, K.; Carrasco, J.; van den Eynde, M.; van Laethem, J-L.; Buyse, M. E.; Hendlisz, A.
errShare
errSave
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
err2024-03-01
err2
PREAI
errXie, W.; Ravi, P.; Buyse, M.; Halabi, S.; Kantoff, P.; Sartor, O.; Soule, H.; Clarke, N.; Dignam, J.; James, N.; Fizazi, K.; Gillessen, S.; Mottet, N.; Murphy, L.; Parulekar, W.; Sandler, H.; Tombal, B.; Williams, S.; Sweeney, C. J.
errShare
errSave
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
err2024-02-24
err0
errOAAI
errKarapetis, C. S.; Liu, H.; Sorich, M. J.; Pederson, L. D.; Van Cutsem, E.; Maughan, T.; Douillard, J. Y.; O'Callaghan, C. J.; Jonker, D.; Bokemeyer, C.; Sobrero, A.; Cremolini, C.; Chibaudel, B.; Zalcberg, J.; Adams, R.; Buyse, M.; Peeters, M.; Yoshino, T.; de Gramont, A.; Shi, Q.
errShare
errSave
Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right?
err2023-11-01
err1
PREAI
errFokas, Emmanouil; Roedel, Claus; Smith, J. Joshua; Garcia-Aguilar, Julio; Buyse, Marc; Glynne-Jones, Robert
errShare
errSave
Generalized pairwise comparisons of prioritized outcomes are a powerful and patient-centric analysis of multi-domain scores
err2023-10-12
err2
errOAAI
errDeltuvaite-Thomas, Vaiva; De Backer, Mickael; Parker, Samantha; Deneux, Marie; Polgreen, Lynda E.; O'Neill, Cara; Salvaggio, Samuel; Buyse, Marc
errShare
errSave
ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
err2023-10-01
err1
PREAI
errXie, W.; Ravi, P.; Buyse, M. E.; Halabi, S.; Kantoff, P. W.; Sartor, O.; Soule, H. R.; Clarke, N.; Collette, L.; Dignam, J.; James, N. D.; Fizazi, K.; Gillessen, S.; Mottet, N.; Murphy, L. R.; Parulekar, W. R.; Sandler, H.; Tombal, B.; Williams, S.; Sweeney, C.
errShare
errSave
Assessing PSA
err2023-10-01
err0
PREAI
errHalabi, S.; Roy, A.; Guo, S.; Rydzewska, L.; Godolphin, P. J.; Parmar, M. K.; Hussain, M.; Tangen, C.; Thompson, I. M.; Carducci, M. A.; Smith, M. R.; Morris, M. J.; Gravis, G.; Dearnaley, D.; Verhagen, P.; Goto, T.; James, N. D.; Buyse, M. E.; Tierney, J.; Sweeney, C.
errShare
errSave
Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
err2023-10-01
err0
errOAAI
errMohr, P.; Squifflet, P.; Saad, E. D.; Larkin, J.; Kurt, M.; Moshyk, A.; Ejzykowicz, F.; Buyse, M. E.
errShare
errSave
Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium
err2023-10-01
err0
PREAI
errRavi, P.; Xie, W.; Buyse, M. E.; Halabi, S.; Kantoff, P. W.; Sartor, O.; Attard, G.; Clarke, N. W.; D'Amico, A.; Dignam, J.; James, N. D.; Fizazi, K.; Gillessen, S.; Parulekar, W. R.; Sandler, H.; Spratt, D.; Sydes, M. R.; Tombal, B.; Williams, S.; Sweeney, C.
errShare
errSave
Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis
err2023-08-04
err3
PREAI
errShahnam, Adel; Nindra, Udit; Desai, Jayesh; Hui, Rina; Buyse, Marc; Hopkins, Ashley M.; Sorich, Michael J.
errShare
errSave
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration
err2023-06-01
err19
errOAAI
errJackson, Timothy L.; Slakter, Jason; Buyse, Marc; Wang, Kun; Dugel, Pravin U.; Wykoff, Charles C.; Boyer, David S.; Gerometta, Michael; Baldwin, Megan E.; Price, Clare F.
errShare
errSave
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
err2023-05-01
err14
errOAAI
errHolmes, Frankie A.; Moy, Beverly; Delaloge, Suzette; Chia, Stephen K. L.; Ejlertsen, Bent; Mansi, Janine; Iwata, Hiroji; Gnant, Michael; Buyse, Marc; Barrios, Carlos H.; Silovski, Tajana; Separovic, Robert; Bashford, Anna; Zotano, Angel Guerrero; Denduluri, Neelima; Patt, Debra; Gokmen, Erhan; Gore, Ira; Ii, John W. Smith; Loibl, Sibylle; Masuda, Norikazu; Tomasevic, Zorica; Petrakova, Katarina; DiPrimeo, Daniel; Wong, Alvin; Martin, Miguel; Chan, Arlene
errShare
errSave
The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustration
err2022-10-05
err2
errOAAI
errJamoul, Corinne; Collette, Laurence; Coart, Elisabeth; D'Hollander, Koenraad; Burzykowski, Tomasz; Saad, Everardo D.; Buyse, Marc
errShare
errSave